Abstract Details

Title Thalamic Structural Connectivity Alterations in Essential Tremor Associated with REM Sleep Behaviour Disorder

Topic Movement Disorders

Presentation(s) P5 - Poster Session 5 (11:45 AM-12:45 PM)

Poster/Presentation
Number 17-008

Objective We aimed at investigating investigated thalamic regions in Essential Tremor (ET) patients with and without REM sleep behavior disorder (RBD), using a graph theoretical analysis.

Background RBD is a rare REM-parasomnia, now considered a non-motor symptom of ET. Distinct structural alterations in the thalamus, as a key region modulating REM sleep, have been reported in patients with idiopathic and Parkinson’s disease-related forms.

Design/Methods

MRI data were acquired from 96 participants (41 ET, 10 ET with polysomnographic-confirmed RBD, ET-RBD, 45 controls). T1-weighted scans were obtained, and grey matter volumes were estimated across 28 thalamic regions of the AAL3 template (Cat12 toolbox). An adjacency matrix for each group was calculated using Pearson correlation. Group-specific matrices were extracted and nodal measures such as centrality measures and clustering coefficient were calculated. Differences between ET groups were computed using a set of 10000 random networks.

Results

Among analyzed thalamic regions, ET-RBD patients showed increased local strength and weighted clustering coefficient in Geniculate Body and increased Betweenness centrality in Right Pulvinar Inferior Nucleus (p=0.05 FDR-corrected). Moreover, ET-RBD patients showed an increased strength and weighted clustering coefficient in Left Lateral Geniculate Body and Right Medial Geniculate Body, compared to controls (p=0.05 FDR-corrected).

Conclusions

Our study demonstrates, for the first time, that the presence of RBD in ET is associated with an altered structural connectivity in thalamic regions. Our findings support the pathophysiologic role of the thalamus in the complex circuit causing RBD, in this particular ET phenotype.

Authors/Disclosures
Salvatore Mazzeo (Policlinico San Donato S.p.A.) PRESENTER	Mr. Mazzeo has nothing to disclose.
Elisa Bortolin, PhD	Dr. Bortolin has nothing to disclose.
Camilla calomino, PhD	Miss calomino has nothing to disclose.
Rita Nistico, MD	Prof. Nistico has nothing to disclose.
Giulia Bruschi	Dr. Bruschi has nothing to disclose.
Maria Vittoria Corbari, MSc in Psychology	Ms. Corbari has nothing to disclose.
Andrea Quattrone, MD, PhD	Prof. Quattrone has nothing to disclose.
Aldo Quattrone, MD	Prof. Quattrone has nothing to disclose.
Fabiana Novellino, MD	Prof. Novellino has nothing to disclose.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit)	Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Maria Salsone ("Vita-Salute" San Raffaele University, IRCCS Policlinico San Donato)	No disclosure on file

��ɫ��

��ɫ��